What Are Senolytics? The Anti-Ageing Science Moving from Mouse Labs to Human Trials

Search for senolytics and you will be told that medicine is close to clearing the worn-out cells that drive ageing. So we did something the coverage rarely does. We went to the public trial registry and counted what has actually been tested in people.

On 14 August 2026, a search of ClinicalTrials.gov for studies tagged “senolytic” returned 31 registered trials. Four have finished. Between those four, 209 people were enrolled. The largest had 75 participants. The smallest had five. Seven more have been withdrawn, terminated, suspended, or have gone silent without posting an update past their expected completion date.

That is the entire completed human evidence base for the most-hyped idea in ageing biology. Not one study has been registered as a stand-alone Phase 3. This article explains what senescent cells are, what senolytics do to them, and then sets out every registered trial and what became of it — including the ones that failed.

None of that means the science is wrong. The biology underneath it is some of the most convincing work in modern ageing research. It means the gap between what has been shown in mice and what has been shown in people is much wider than the headlines suggest, and that gap is worth understanding precisely.

What Is Cellular Senescence?

There is a certain kind of cell in your body that has stopped dividing but refuses to die. It is not cancerous. It is not dead. It is something in between — a cell that has reached the end of its useful life, triggered an internal alarm, and entered a permanent state of arrested activity called cellular senescence.

In small numbers, these cells are useful. They appear at wound sites to help orchestrate repair, act as a brake on the early growth of tumours, and help shape organs during foetal development. In these contexts, senescence is a feature of biology, not a bug.

But as you age, senescent cells accumulate, and the immune system that is supposed to clear them becomes less efficient at doing so. By your sixties, seventies and eighties they are present throughout the body in significant numbers, secreting inflammatory molecules into surrounding tissue. That secretion — the senescence-associated secretory phenotype, or SASP — damages neighbouring cells, disrupts tissue architecture, and feeds the chronic inflammation now linked to most major diseases of ageing.

The term was coined by the American cell biologists Leonard Hayflick and Paul Moorhead in 1961, when they observed that human fibroblasts in culture would divide a finite number of times — roughly 50 — and then stop. That maximum became known as the Hayflick limit. Since then it has become clear that senescence can be triggered by far more than telomere shortening: DNA damage from radiation, oxidative stress and genotoxic chemicals; oncogene activation, in which switching on a cancer-promoting gene triggers senescence as a protective response; and mitochondrial dysfunction, which generates reactive oxygen species that damage DNA and signal for arrest.

At the molecular level, senescence is enforced by two tumour-suppressor pathways: p53/p21 and p16/Rb. DNA damage and telomere shortening trigger a DNA-damage response that activates p53, which drives production of p21; p21 then blocks the cyclin-dependent kinases that would otherwise push the cell through division. The p16/Rb pathway works in parallel to the same end. Both converge on one outcome: a cell that cannot divide. Senescent cells are also recognisable under a microscope — large, flattened and granular, with elevated beta-galactosidase activity and accumulated DNA-damage foci.

The SASP: Why Senescent Cells Are So Damaging

The senescence-associated secretory phenotype is the most consequential feature of these cells. It is the mechanism by which a relatively small number of non-dividing cells can cause damage far beyond their immediate neighbourhood. The SASP is a mixture of secreted factors: pro-inflammatory cytokines including IL-6, IL-8 and TNF-α; matrix metalloproteinases that degrade the extracellular matrix; growth factors such as VEGF; and chemokines that recruit immune cells.

The consequences are wide-ranging. Locally, the SASP degrades the structural environment around the cell, disrupts healthy neighbours, and can induce senescence in those neighbours through a process called paracrine senescence, spreading the state from cell to cell. Systemically, SASP factors enter the bloodstream and feed the chronic low-grade inflammation that characterises ageing — sometimes called inflammaging — now recognised as a driver of age-related disease across nearly every organ system.

Crucially, the SASP is not a single fixed cocktail. Its composition varies by cell lineage, metabolic state and the stressor that induced senescence. Senescent cells also deploy immune-evasion mechanisms that limit their clearance by cytotoxic lymphocytes and natural killer cells — part of why they accumulate with age even while the immune system remains partially functional. That heterogeneity turns out to matter enormously when you try to design a drug against them, as the trial record below shows.

The Mouse Experiments That Changed Everything

The case for targeting senescent cells was built on a series of mouse experiments at the Mayo Clinic. In a 2011 paper in Nature, Darren Baker, Jan van Deursen and colleagues used a genetically engineered mouse in which senescent cells could be selectively eliminated: the cells carried a drug-activatable suicide gene tied to p16Ink4a, a senescence marker. Clearing those cells delayed the onset of cataracts, muscle wasting and fat-tissue dysfunction.

A follow-up in 2016 went further, reporting that clearing naturally occurring p16-positive cells extended median lifespan in normally ageing mice and delayed tumour formation. Then in 2018, writing in Nature Medicine, Ming Xu and colleagues showed that transplanting small numbers of senescent cells into young, healthy mice caused lasting physical dysfunction — evidence that these cells are not merely a correlate of ageing but a cause of it. Senolytic treatment partly reversed the damage and extended survival in older animals.

These are strong results, independently replicated, and they are the reason the field exists. The implication — that one drug class might delay several age-related diseases simultaneously — is genuinely radical. Everything that follows is about what happened when that idea met human beings.

What Are Senolytics? The Drugs Being Developed

Senolytics are compounds that selectively induce apoptosis — programmed cell death — in senescent cells while leaving healthy cells relatively unaffected. The selectivity arises from the biology of senescence itself: senescent cells resist normal death signals because they upregulate pro-survival pathways, and senolytic drugs target those pathways.

The first identified were dasatinib, a tyrosine-kinase inhibitor already approved for leukaemia, and quercetin, a plant flavonoid. Dasatinib targets pro-survival signals in certain senescent cell types, particularly fat-cell progenitors; quercetin hits different pathways across a broader range. Together, the combination known as D+Q showed greater activity than either alone and became the most widely studied senolytic regimen. Fisetin, another flavonoid, was later identified as the most potent senolytic among ten flavonoids screened, and now appears in more registered trials than any other single compound.

It is worth distinguishing senolytics from senomorphics. Senomorphics — including rapamycin and certain JAK inhibitors — reduce the damage caused by senescent cells without eliminating them, by suppressing SASP secretion. They are generally better tolerated but do not address the accumulation of dysfunctional cells. Other senolytic candidates include navitoclax, a BCL-2 inhibitor with potent activity that causes thrombocytopenia in humans; UBX0101, an MDM2/p53 inhibitor tested in knee osteoarthritis; and CAR-T-based senolytics, engineered immune cells still confined to animal work.

Every Registered Senolytic Trial, and What Became of It

Press coverage tends to describe senolytic research as a single accelerating programme. The registry tells a more scattered story. What follows is the status of all 31 studies tagged “senolytic” on 14 August 2026, grouped by what actually happened to them.

Four trials have run their full course:

• Knee osteoarthritis — 75 participants, Phase 1/2, Steadman Philippon Research Institute, completed February 2023 (NCT04210986). The largest completed senolytic trial to date.
• Skeletal health in older adults — 74 participants, Phase 2, led by Sundeep Khosla at Mayo Clinic, completed June 2023 (NCT04313634).
• COVID-19 in older adults — 55 participants, Phase 2, fisetin, led by James Kirkland, completed September 2022 (NCT04771611).
• Alzheimer’s disease — five participants, Phase 1/2, UT Health San Antonio, completed January 2023 (NCT04063124). An open-label safety pilot, not an efficacy study.

Twenty further trials are live: eight recruiting, seven active but closed to new participants, four not yet open, and one enrolling by invitation. They reach well beyond ageing itself — secondary progressive multiple sclerosis, sepsis, peripheral artery disease, HIV, osteoporosis, heart failure and childhood-cancer survivorship among them. Their combined planned enrolment is roughly 1,780 people, but planned enrolment is a target, not a result.

The group that receives least attention is the one that failed. Three trials were withdrawn before enrolling anyone, two of them in osteoarthritis. One was terminated: a fisetin study in nursing-home residents with COVID-19 (NCT04537299). One is suspended, and two carry the status unknown — the registry’s term for a study whose sponsor has stopped posting updates past its expected completion date. Seven of 31 is an attrition rate that no summary of this field mentions.

One pattern stands out across the live studies. Osteoarthritis has now seen more senolytic trials abandoned than completed, which is notable given that joints were among the earliest and most confident targets for this approach.

The Eye Programme the Registry Search Misses

There is a significant exception to those 31, and it matters because it is the most commercially advanced senolytic work anywhere. Unity Biotechnology registers its studies under the compound name rather than the word “senolytic”, so none of them appear in that search. Its drug foselutoclax, formerly UBX1325, is a BCL-xL inhibitor injected directly into the eye to clear senescent cells from damaged retinal blood vessels while sparing healthy ones.

Four Unity trials are registered and all four have completed: a Phase 1 safety study in 19 patients (NCT04537884), the 65-patient BEHOLD study in diabetic macular oedema (NCT04857996), the 51-patient ENVISION study in wet age-related macular degeneration (NCT05275205), and the 52-patient ASPIRE study (NCT06011798).

ASPIRE results were presented at the American Academy of Ophthalmology meeting in October 2025 and reported in the ophthalmic trade press. In patients who had responded poorly to existing anti-VEGF injections, foselutoclax was described as non-inferior to aflibercept across most timepoints through 36 weeks. Two things are worth holding onto. The comparison was non-inferiority rather than superiority, meaning the goal was to match an existing drug rather than beat it. And the finding has been presented at a conference, not published in a peer-reviewed journal. Conference data is a legitimate early signal, not a settled result.

Counting Unity’s programme, the true number of registered senolytic human trials is at least 35. The registry tag alone undercounts the field, which is one reason casual summaries of it are unreliable — and one reason we counted rather than quoted.

What the Published Human Results Actually Show

Registration is not publication. Of the trials above, only a handful have produced peer-reviewed papers, and reading them carefully is the fastest way to calibrate expectations.

The first-in-human senolytic study gave dasatinib and quercetin to 14 people with idiopathic pulmonary fibrosis, a progressive and usually fatal lung-scarring disease. Participants showed improvements in walking distance and other physical-function measures. It was open-label, uncontrolled, and explicitly designed to test feasibility rather than benefit — the authors said so themselves.

A companion study in nine people with diabetic kidney disease is arguably the more important result. After three days of treatment, participants showed measurable reductions in senescent-cell burden in fat and skin tissue, along with falls in circulating SASP factors. This is the clearest human evidence that senolytics do in the body what they are designed to do. It rests on nine participants.

A later randomised, placebo-controlled Phase 1 trial in pulmonary fibrosis again reported on tolerability rather than efficacy. And the Phase 2 bone-health trial, the most rigorous senolytic study run so far, found only limited benefit against control — a sobering result given how dramatic the equivalent mouse data had been. Separately, Unity’s earlier compound UBX0101 failed to beat placebo in Phase 2 for knee osteoarthritis, and that programme was discontinued.

What explains the gap? Mice age far faster than we do and may carry a higher relative senescent-cell burden at the point of treatment. Human trials use disease endpoints rather than the healthspan measures used in animals, and run for months where mouse studies effectively cover a lifetime. Participants may not have had a high enough senescent-cell burden to show a dramatic response. And because the SASP differs between cell types, one drug combination may simply not reach the full spectrum of senescent cells driving a given disease.

The Next Generation: CAR-T and Immune-Based Approaches

The limits of first-generation small molecules have accelerated more targeted approaches. Researchers at Cold Spring Harbor Laboratory have shown that CAR-T cells — the engineered immune cells that transformed leukaemia treatment — can be designed to recognise and destroy senescent cells carrying the surface protein uPAR. In mouse models these improved metabolic function and extended healthspan without apparent toxicity.

A related strategy is partial cellular reprogramming, using Yamanaka factors to reset the epigenetic age of cells and partly reverse senescence without fully dedifferentiating them. Other groups are working to restore the natural killer cells and cytotoxic T lymphocytes that clear senescent cells efficiently in younger people — supplementing the body’s own surveillance rather than replacing its job with a drug. All of this remains animal work. None of it appears in the human registry yet, and that distinction matters when you read confident claims about what is coming.

The Honest Assessment: Where Are We Really?

Set the mouse work beside the human work and the position becomes clear. Senescent cells are real. The SASP is real. Clearing these cells changes outcomes in mice, repeatedly and convincingly. In humans, senolytics have been shown to reduce senescent-cell markers and have proved tolerable at intermittent doses in small groups.

No completed trial has demonstrated that they extend human lifespan, reverse ageing, or treat an age-related disease better than existing care. The largest completed study enrolled 75 people. That is the state of the evidence in August 2026, and anyone telling you otherwise is selling something.

This is not a reason for dismissal. It is a reason for patience. The field sits roughly where cancer immunotherapy sat in the late 1990s: a mechanism that is clearly real, early signals that are genuinely interesting, and an evidence base far too small to support the claims made on its behalf. Checkpoint inhibitors took another fifteen years to become standard care.

The remaining obstacles are specific rather than vague. Biomarkers that reliably measure senescent-cell burden are not yet validated for clinical use, which makes it hard to select the right patients or confirm a drug is working. Selectivity remains difficult, as navitoclax’s effect on platelets illustrates. Tissue access is encouraging for the brain but unproven elsewhere. And SASP heterogeneity suggests one-size-fits-all strategies may have to give way to tissue- and disease-specific ones.

The connection to the wider genetics of ageing is direct. Senescent cells accumulate partly because DNA-repair mechanisms become less efficient with age, and telomere shortening is one of the primary triggers of senescence — explored in our piece on telomeres and ageing. Epigenetic changes are both cause and consequence of senescence, a theme covered in epigenetics and how your environment shapes your genes. Senolytics also sit inside the broader effort to slow ageing, examined in the real science of reverse ageing and what centenarian DNA reveals about longevity.

The twenty trials now running will settle far more than anything published so far. We will update this article as they report.

Frequently Asked Questions

Sources

Primary peer-reviewed research

• Baker et al. — Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders, Nature (2011)
• Baker et al. — Naturally occurring p16Ink4a-positive cells shorten healthy lifespan, Nature (2016)
• Yousefzadeh et al. — Fisetin is a senotherapeutic that extends health and lifespan, EBioMedicine (2018)
• Xu et al. — Senolytics improve physical function and increase lifespan in old age, Nature Medicine (2018)
• Justice et al. — Senolytics in idiopathic pulmonary fibrosis: first-in-human, open-label pilot study, EBioMedicine (2019)
• Hickson et al. — Senolytics decrease senescent cells in humans: diabetic kidney disease, EBioMedicine (2019)
• Nambiar et al. — Dasatinib and quercetin in IPF: randomised, placebo-controlled Phase 1 trial, EBioMedicine (2023)

Trial registry and institutional sources

• ClinicalTrials.gov — all registered studies tagged “senolytic” (retrieved 14 August 2026)
• National Institute on Aging — Senolytic therapy shows subtle impact on age-related bone health in women
• npj Aging — Senolytics: from pharmacological inhibitors to immunotherapies (2024)
• Cell Death Discovery — Hallmarks and mechanisms of cellular senescence (2025)